Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771105 | 0.92 | GSK3B (0.39) | HDAC8SLC22A12GSK3B | |
| SCHEMBL5771831 | 0.85 | HDAC8 (0.34) | HDAC8MAPK14GSK3BCXCR2 | |
| SCHEMBL5773577 | 0.85 | NAMPT (0.35) | HDAC8MAPK14GSK3B | |
| SCHEMBL5770760 | 0.82 | MAPK1 (0.35) | HDAC8 | |
| SCHEMBL5772670 | 0.82 | POLQ (0.40) | HDAC8GSK3B | |
| SCHEMBL5775478 | 0.81 | HTT (0.38) | HDAC8 | |
| SCHEMBL5777440 | 0.79 | HDAC8 (0.35) | HDAC8 | |
| SCHEMBL5771361 | 0.78 | NAMPT (0.42) | — | |
| SCHEMBL5773324 | 0.78 | CYP3A4 (0.41) | HDAC8 | |
| SCHEMBL5774897 | 0.77 | MPO (0.35) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | HDAC8 639/4885MAPK14 1376/4885MAPK10 2760/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | HDAC8 569/4885MAPK14 1203/4885MAPK10 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.